Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.

Beaver SK, Mesa-Torres N, Pey AL, Timson DJ.

Biochim Biophys Acta Proteins Proteom. 2019 Jul - Aug;1867(7-8):663-676. doi: 10.1016/j.bbapap.2019.05.002. Epub 2019 May 12. Review.

PMID:
31091472
2.

Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I.

Fernández-Higuero JÁ, Betancor-Fernández I, Mesa-Torres N, Muga A, Salido E, Pey AL.

Adv Protein Chem Struct Biol. 2019;114:119-152. doi: 10.1016/bs.apcsb.2018.09.003. Epub 2018 Nov 28. Review.

PMID:
30635080
3.

High-Affinity Chemotaxis to Histamine Mediated by the TlpQ Chemoreceptor of the Human Pathogen Pseudomonas aeruginosa.

Corral-Lugo A, Matilla MA, Martín-Mora D, Silva Jiménez H, Mesa Torres N, Kato J, Hida A, Oku S, Conejero-Muriel M, Gavira JA, Krell T.

mBio. 2018 Nov 13;9(6). pii: e01894-18. doi: 10.1128/mBio.01894-18.

4.

Phosphorylation compromises FAD binding and intracellular stability of wild-type and cancer-associated NQO1: Insights into flavo-proteome stability.

Medina-Carmona E, Rizzuti B, Martín-Escolano R, Pacheco-García JL, Mesa-Torres N, Neira JL, Guzzi R, Pey AL.

Int J Biol Macromol. 2019 Mar 15;125:1275-1288. doi: 10.1016/j.ijbiomac.2018.09.108. Epub 2018 Sep 19.

PMID:
30243998
5.

Insight into the specificity and severity of pathogenic mechanisms associated with missense mutations through experimental and structural perturbation analyses.

Medina-Carmona E, Betancor-Fernández I, Santos J, Mesa-Torres N, Grottelli S, Batlle C, Naganathan AN, Oppici E, Cellini B, Ventura S, Salido E, Pey AL.

Hum Mol Genet. 2019 Jan 1;28(1):1-15. doi: 10.1093/hmg/ddy323.

PMID:
30215702
6.

Evolutionary Divergent Suppressor Mutations in Conformational Diseases.

Mesa-Torres N, Betancor-Fernández I, Oppici E, Cellini B, Salido E, Pey AL.

Genes (Basel). 2018 Jul 13;9(7). pii: E352. doi: 10.3390/genes9070352. Review.

7.

Improving the Activity and Stability of Human Galactokinase for Therapeutic and Biotechnological Applications.

McAuley M, Mesa-Torres N, McFall A, Morris S, Huang M, Pey AL, Timson DJ.

Chembiochem. 2018 May 18;19(10):1088-1095. doi: 10.1002/cbic.201800025. Epub 2018 Apr 26.

PMID:
29505688
8.

Enhanced vulnerability of human proteins towards disease-associated inactivation through divergent evolution.

Medina-Carmona E, Fuchs JE, Gavira JA, Mesa-Torres N, Neira JL, Salido E, Palomino-Morales R, Burgos M, Timson DJ, Pey AL.

Hum Mol Genet. 2017 Sep 15;26(18):3531-3544. doi: 10.1093/hmg/ddx238.

PMID:
28911204
9.

Caenorhabditis elegans AGXT-1 is a mitochondrial and temperature-adapted ortholog of peroxisomal human AGT1: New insights into between-species divergence in glyoxylate metabolism.

Mesa-Torres N, Calvo AC, Oppici E, Titelbaum N, Montioli R, Miranda-Vizuete A, Cellini B, Salido E, Pey AL.

Biochim Biophys Acta. 2016 Sep;1864(9):1195-1205. doi: 10.1016/j.bbapap.2016.05.004. Epub 2016 May 11.

PMID:
27179589
10.

Erratum: Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands.

Medina-Carmona E, Palomino-Morales RJ, Fuchs JE, Padín-Gonzalez E, Mesa-Torres N, Salido E, Timson DJ, Pey AL.

Sci Rep. 2016 Mar 4;6:21939. doi: 10.1038/srep21939. No abstract available.

11.

Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands.

Medina-Carmona E, Palomino-Morales RJ, Fuchs JE, Padín-Gonzalez E, Mesa-Torres N, Salido E, Timson DJ, Pey AL.

Sci Rep. 2016 Feb 3;6:20331. doi: 10.1038/srep20331. Erratum in: Sci Rep. 2016;6:21939.

12.

Molecular recognition of PTS-1 cargo proteins by Pex5p: implications for protein mistargeting in primary hyperoxaluria.

Mesa-Torres N, Tomic N, Albert A, Salido E, Pey AL.

Biomolecules. 2015 Feb 13;5(1):121-41. doi: 10.3390/biom5010121.

13.

The lower limits for protein stability and foldability in primary hyperoxaluria type I.

Mesa-Torres N, Salido E, Pey AL.

Biochim Biophys Acta. 2014 Dec;1844(12):2355-65. doi: 10.1016/j.bbapap.2014.10.010. Epub 2014 Oct 18.

PMID:
25461797
14.

The metastability of human UDP-galactose 4'-epimerase (GALE) is increased by variants associated with type III galactosemia but decreased by substrate and cofactor binding.

Pey AL, Padín-Gonzalez E, Mesa-Torres N, Timson DJ.

Arch Biochem Biophys. 2014 Nov 15;562:103-14. doi: 10.1016/j.abb.2014.07.030. Epub 2014 Aug 19.

PMID:
25150110
15.

The consensus-based approach for gene/enzyme replacement therapies and crystallization strategies: the case of human alanine-glyoxylate aminotransferase.

Mesa-Torres N, Yunta C, Fabelo-Rosa I, Gonzalez-Rubio JM, Sánchez-Ruiz JM, Salido E, Albert A, Pey AL.

Biochem J. 2014 Sep 15;462(3):453-63. doi: 10.1042/BJ20140250.

PMID:
24957194
16.

The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I.

Mesa-Torres N, Fabelo-Rosa I, Riverol D, Yunta C, Albert A, Salido E, Pey AL.

PLoS One. 2013 Aug 27;8(8):e71963. doi: 10.1371/journal.pone.0071963. eCollection 2013.

17.

Structural and energetic basis of protein kinetic destabilization in human phosphoglycerate kinase 1 deficiency.

Pey AL, Mesa-Torres N, Chiarelli LR, Valentini G.

Biochemistry. 2013 Feb 19;52(7):1160-70. doi: 10.1021/bi301565m. Epub 2013 Feb 4.

PMID:
23336698

Supplemental Content

Loading ...
Support Center